Saturday, July 11, 2026

Drug profile · INN

tenofovir disoproxil + emtricitabine + efavirenz

tenofovir disoproxil + emtricitabine + efavirenz (TENOFOVIR DISOPROXIL EMTRICITABINE EFAVIRENZ VIATRIS 300/200/600) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

TGA: approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — tenofovir disoproxil + emtricitabine + efavirenz

Quick answer

tenofovir disoproxil + emtricitabine + efavirenz (TENOFOVIR DISOPROXIL EMTRICITABINE EFAVIRENZ VIATRIS 300/200/600) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

Key facts

INN tenofovir disoproxil + emtricitabine + efavirenz
Brand TENOFOVIR DISOPROXIL EMTRICITABINE EFAVIRENZ VIATRIS 300/200/600

Approval history

Authority Status Date
TGA approved

Pipeline programs

  1. Granexin® gel (200 μM) Phase 2 · United Therapeutics Europe · Second Degree Burn
  2. AMBER Phase 1 · TESARO Bio Netherlands · Patients with Advanced Solid Tumors
  3. Phenytoin single dose (300 mg) Unknown · United Therapeutics Europe · Healthy

Frequently asked questions

What is tenofovir disoproxil + emtricitabine + efavirenz?

tenofovir disoproxil + emtricitabine + efavirenz (TENOFOVIR DISOPROXIL EMTRICITABINE EFAVIRENZ VIATRIS 300/200/600) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

What is the brand name for tenofovir disoproxil + emtricitabine + efavirenz?

TENOFOVIR DISOPROXIL EMTRICITABINE EFAVIRENZ VIATRIS 300/200/600 is a marketed brand name for tenofovir disoproxil + emtricitabine + efavirenz. Check FDA Drugs@FDA for the current US label holder and prescribing information.